Investing.com UK - Financial Markets Worldwide

Clinuvel Pharmaceuticals Ltd (CUV)

Sydney
Symbol
Exchange
Currency
CUV·Sydney·AUD
CLVLF·OTC Markets·USD
CLVLY·OTC Markets·USD
CUV·TradeGate·EUR
Currency in AUD
9.73
-0.03(-0.31%)
Closed·

Clinuvel Pharmaceuticals (ASX:CUV) Annual Report

Key Ratios

P/E Ratio12.6
Price/Book2.73
Debt / Equity0.33%
Return on Equity19.59%
Dividend Yield0.51%
EBITDA49.32M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
30/06
2016
30/06
2017
30/06
2018
30/06
2019
30/06
2020
30/06
2021
30/06
2022
30/06
2023
30/06
2024
30/06
Income Statement
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa32.5748.3265.7278.3288.18
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa25.2644.1556.4770.880.45
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa12.2528.5735.5544.1348.57
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa15.0524.7320.8830.635.64
Balance Sheet
Total Assets
aa.aaaa.aaaa.aaaa.aaaa.aa81.54108.57143.95193.71231.12
Total Current Liabilities
aa.aaaa.aaaa.aaaa.aaaa.aa8.268.7113.7325.4925.21
Total Equity
aa.aaaa.aaaa.aaaa.aaaa.aa72.0798.74125.56164.63203.01
Cash Flow
Levered Free Cash Flow
aa.aaaa.aaaa.aaaa.aaaa.aa9.48.0633.2532.3323.45
Cash from Operations
aa.aaaa.aaaa.aaaa.aaaa.aa14.1919.2639.8736.9137.05
Cash from Investing
aa.aaaa.aaaa.aaaa.aaaa.aa-0.89-0.85-0.43-31.85-29.03
Cash from Financing
aa.aaaa.aaaa.aaaa.aaaa.aa-1.49-1.48-1.5-2.24-3.57
Net Change in Cash
aa.aaaa.aaaa.aaaa.aaaa.aa12.4815.9438.824.483.31
* In Millions of AUD (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.77%
Dividend Yield
0.51%
Industry Median 1.37%
Annualised payout
0.05
Paid annually
5-Years Growth
+14.87%
Growth Streak
Unlock

Analyst Ratings

7 Buy
0 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.63
(+153.10% Upside)

Earnings

Latest Release
Feb 26, 2025
EPS / Forecast
0.28 / 25.90
Revenue / Forecast
35.65M / 34.13M
EPS Revisions
a
a
Unlock
Last 90 days

FAQ

What were Clinuvel Pharmaceuticals's earnings for the latest quarter?

The Clinuvel Pharmaceuticals EPS (TTM) is 0.77. Clinuvel Pharmaceuticals reported sales of 35.65, net income of 14.08, and EPS of 0.28 for the latest quarter.

What was Clinuvel Pharmaceuticals's net income for the latest quarter?

Clinuvel Pharmaceuticals's net income for the latest quarter was 14.08.

How did Clinuvel Pharmaceuticals's performance compare year-over-year in the latest quarter?

The company's revenue moved from 55.38 in the previous quarter to 35.65 in the latest quarter, and net income moved from 24.70 to 14.08 compared to the previous quarter.

What is Clinuvel Pharmaceuticals's net profit margin on a TTM basis?

Clinuvel Pharmaceuticals's trailing twelve months (TTM) net profit margin is 40.41%.

How does Clinuvel Pharmaceuticals's debt to equity ratio compare to industry standards?

Clinuvel Pharmaceuticals's total debt-to-equity ratio is 0.33%.

What is Clinuvel Pharmaceuticals's return on investment on a TTM basis?

Clinuvel Pharmaceuticals's trailing twelve months (TTM) return on investment (ROI) is 19.59%.

Did Clinuvel Pharmaceuticals gain or lose cash last quarter?

In the latest quarter, Clinuvel Pharmaceuticals's net change in cash was -18.38 million.

What were Clinuvel Pharmaceuticals's total assets and liabilities in the latest quarter?

As of the latest quarter, Clinuvel Pharmaceuticals reported total assets of 236.20 million and total liabilities of 13.10 million.

How has Clinuvel Pharmaceuticals's total revenue grown this year?

Clinuvel Pharmaceuticals's total revenue was 55.38 in the previous quarter and 35.65 in the latest quarter.

What is Clinuvel Pharmaceuticals's gross margin on a TTM basis?

Clinuvel Pharmaceuticals's trailing twelve months (TTM) gross margin is 90.83%.

What was Clinuvel Pharmaceuticals's revenue per share for the latest quarter?

Clinuvel Pharmaceuticals's revenue per share for the latest quarter was 31.61.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.